- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01179646
Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets
A Pharmacokinetic Study to Determine the Bioequivalence of a Test 40 mg Pantoprazole Delayed-Release Tablet, Compared to a Marketed 40 mg Pantoprazole Delayed-Release Tablet (Protonix, Wyeth Pharmaceuticals) When Administered to Healthy Adult Subjects in the Fasted State
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- MDS Pharma Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non tobacco/nicotine-using (6 months minimum) healthy males and females between 19 and 50 years of age.
- Body weight from 15% below or 15% above, inclusive, the ideal weight for height and estimated frame, as adapted from the 1983 Metropolitan Life Table.
- Female subjects were surgically sterile, at least two years postmenopausal, or if sexually active, had a partner who had been vasectomized for at least 6 months, or agreed to utilize one of the following forms of contraception: barrier (condom with spermicide or diaphragm with spermicide), IUD, or hormonal (oral, implant, transdermal patch, or injection) for the following specified times.
Subjects using hormonal contraceptives were on a stable dose for 3 months prior to dosing, or they agreed to also use a barrier method of birth control from screening through completion of the study. Subjects having an intrauterine device (IUD) must have had the IUD in place for at least 2 months prior to dosing, or they agreed to also use a barrier method of birth control from screening through completion of the study. For other forms of birth control, the subject had used the method at least 2 weeks prior to screening and agreed to use the method through completion of the study.
- Voluntary consent to participate in this study as demonstrated by signing the informed consent form.
Exclusion Criteria:
- Persons of Asian origin.
- Females who were pregnant or lactating.
- History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject or impact the validity of the study results.
- History of hypersensitivity, allergic or adverse response to pantoprazole or related drugs.
- Positive results from HIV antibody screen, hepatitis B surface antigen screen, and/or hepatitis C antibody screen.
- Participation in a previous clinical trial within 30 days prior to study initiation.
- Donation of one pint or more of whole blood within 56 days prior to study initiation.
- Donation of 2 units of red blood cells within 112 days prior to study initiation.
- Donation of plasma with 7 days prior to study initiation.
- Difficulty in swallowing medication or any gastrointestinal disease that could affect the drug absorption.
- Abnormal diet or substantial changes in eating habits within 30 days prior to study initiation. Examples included, but were not limited to, vegetarian, fasting, or liquid supplement, etc.
- Treatment with any known enzyme-altering agents (barbiturates, phenothiazines, or cimetidine, etc.) within 30 days prior to study initiation.
- Use of any prescription medication (except hormonal contraceptives for females) within 14 days prior to study initiation.
- Use of any over-the-counter (OTC) medication, including mega-dose vitamins, analgesics, herbal/nutritional supplements, and antacids, within 7 days prior to study initiation.
- Positive urine screen for alcohol or drugs of abuse.
- Unwilling to eat the food as provided in the study menu.
- Hemoglobin <12.0 g/dL.
- History of alcohol or drug abuse within 2 years prior to dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Protonix
Protonix 40 mg DR Tablet
|
Single dose crossover BE study
Other Names:
|
Experimental: Pantoprazole
Pantoprazole 40 mg DR Tablet
|
Single dose crossover BE study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax (maximum observed concentration of drug substance in plasma)
Time Frame: 16 hours
|
16 hours
|
AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration)
Time Frame: 16 hours
|
16 hours
|
AUC0-inf area under the concentration-time curve from time zero to infinity)
Time Frame: 16 hoyurs
|
16 hoyurs
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alan Marion, MD, PhD, MDS Pharma Services
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP796
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
-
Kremers Urban Development CompanyCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Istituto Oncologico Veneto IRCCSCompletedGlioblastoma MultiformeItaly
-
Kirby InstituteRecruitingHepatitis C | Liver Cirrhoses | Liver InflammationAustralia
-
Teva Pharmaceuticals USACompleted
-
Torrent Pharmaceuticals LimitedCompleted
-
Torrent Pharmaceuticals LimitedCompleted
-
Istituto Oncologico Veneto IRCCSBayerNot yet recruitingMeningioma, MalignantItaly
-
Teva Pharmaceuticals USACompleted